ClinicalTrials.gg
TerminatedNCT07228559Updated May 11, 2026

A Study of Avoralstat In Participants With Diabetic Macular Edema

A Phase 1 interventional study of avoralstat in Diabetic Macular Edema (DME), sponsored by BioCryst Pharmaceuticals. Terminated at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by BioCryst Pharmaceuticals · Phase 1, Interventional, and Treatment

Why this study was terminated
Strategic decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies in Macular Edema with a site in Australia — 3 open to participants now, 6 under way, 2 of them phase 3. Macular Edema · Australia.

Enrollment
36th of 36
3 · median 292
Started
2025
with 2 others
Phase 1
4 of 36
1 open now
Registered
35th of 36
by date
Lead sponsor
1 of 36
BioCryst Pharmaceuticals

Among the 36 studies in Macular Edema with a site in Australia, this one is the 36th largest by enrollment, is one of 3 that started in 2025, is one of 4 in phase 1, and was the 35th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

3 of the 36 studies in Macular Edema with a site in Australia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 44 Macular Edema studies recruiting now, 31 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Macular Edema with a site in Australia, or all of them as a file.
02

Study summary

The goal of this study is to assess the safety and therapeutic potential of a single dose of avoralstat in adult participants with DME.

Read the detailed description

Study BCX4161-111 is an open-label, single ascending dose study with 24 weeks follow-up in participants with DME. Three cohorts with a minimum of 3 participants enrolled in each cohort with 3 dose levels of avoralstat (low, medium, high) are planned.

03

Conditions studied

  • Diabetic Macular Edema (DME)

Browse trials for

Keywords

  • single ascending dose
  • safety
  • pharmacokinetics
  • suprachoroidal injection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Male or female aged 18 years or older
  2. A (HbA1c) \< 10% at screening
  3. Diagnosis of DME with center involvement requiring medical treatment within 6 months of screening and decreased visual acuity attributable to DME
  4. Mild-to-severe non-proliferative diabetic retinopathy (NPDR) with DRSS \< 61 in the study eye at screening
  5. BCVA between 35 and 80 ETDRS letters (20/25 to 20/200 Snellen equivalent), inclusive, in the study eye at screening
  6. CST measured by Heidelberg OCT between 325 and 600 μm in the study eye at screening

Key Exclusion Criteria:

  1. Participants who have previously received more than 3 anti-VEGF injections
  2. Any history of retinal surgery or other surgical intervention for diabetic ocular complications or anticipated need for use of laser photocoagulation course of any of the procedures listed in the criteria in the study eye during the study period
  3. Current medically untreated diabetes mellitus or previous medically untreated diabetes mellitus with initiation of oral or injectable anti-diabetic medication ≤ 3 months prior to screening
  4. Active intraocular or periocular infection or active intraocular inflammation in the study eye
  5. Intraocular surgery ≤ 3 months prior to screening or anticipated need for ocular surgery in the study eye during the study period
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Single dose suprachoroidal injection of avoralstat

    Drug: avoralstat

Interventions

  • BCX4161 for suprachoroidal injection

06

What researchers measure

Primary outcomes

  1. The safety and tolerability of avoralstat in participants with DME. Incidence and severity of ocular (study eye) and systemic treatment emergent adverse events (TEAEs).

    Time frame: From screening through EOS (Week 24)

Secondary outcomes

  1. Therapeutic potential of avoralstat in participants with DME. Trends in central subfield thickness (CST) as assessed by spectral domain optical coherence tomography (SD-OCT).

    Time frame: From baseline through Weeks 12 and 24

  2. Therapeutic potential of avoralstat in participants with DME. Trends in Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA).

    Time frame: From baseline through Weeks 12 and 24

07

Study locations

8 sites
  • Investigative Site 6
    Sacramento, California 95825, United States
  • Investigative Site 7
    Katy, Texas 77494, United States
  • Investigative Site 8
    The Woodlands, Texas 77384, United States
  • Investigative Site 1
    Sydney, New South Wales, Australia
  • Investigative Site 2
    Sydney, New South Wales, Australia
  • Investigative Site 3
    Sydney, New South Wales, Australia
  • Investigative Site 4
    Adelaide, South Australia, Australia
  • Investigative Site 5
    Melbourne, Victoria, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2025 to primary completion in Apr 2026, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2025
First posted
Nov 14, 2025
StartActual
Oct 2, 2025
Primary completionActual
Apr 17, 2026
CompletionActual
Apr 17, 2026
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07228559
Responsible party
Sponsor
First posted
Nov 14, 2025
Start date
Oct 2, 2025
Primary completion
Apr 17, 2026
Completion
Apr 17, 2026
Last update
May 11, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avoralstat

Start the discussion